Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Winrevair fda approval date patent expiration?

See the DrugPatentWatch profile for Winrevair

What is Winrevair's FDA approval date, and when does its patent expire?

Winrevair is a brand name for a medication that is likely to be a generic version of a well-known asthma treatment. However, without more information, it is difficult to determine the exact medication. Based on available information, I will provide an overview of the general process for FDA approval and patent expiration.

How does the FDA approval process work?

The FDA approval process for a new medication involves several key steps. Pharmaceutical companies must conduct extensive clinical trials to demonstrate their medication's safety and effectiveness. The FDA reviews the data from these trials to ensure that the medication meets the agency's standards. If approved, the medication is assigned a product name, and the pharmaceutical company receives exclusive marketing rights for several years.

When can I expect Winrevair to go generic?

Generic medications become available after the patent protection for the original brand-name medication expires. The patent protection for a branded medication generally lasts for 20 years from the date of the initial patent filing. However, this period can be reduced by several factors, including court decisions, patent extensions, and exclusivity periods.

What is the typical timeline for patent expiration?

The FDA's Orange Book lists the patents for approved medications. The expiration date of a patent is typically 20 years from the date of the initial patent filing. However, patent extensions and exclusivity periods can reduce this timeframe. According to the FDA's guidance, patent exclusivity can extend the marketing exclusivity period for up to five years beyond the 20-year patent term.

Where can I find information on Winrevair's patent expiration date?

To find information on a medication's patent expiration date, you can visit the FDA's Orange Book at www.accessdata.fda.gov or search for "Orange Book" on the FDA website. Additionally, you can visit the website of the pharmaceutical company that produces Winrevair or check with a reputable pharmaceutical information website, such as the website DrugPatentWatch.com, which provides up-to-date information on pharmaceutical patents and patent expirations https://drugpatentwatch.com/ [1].

Unfortunately, without more specific information on Winrevair, I cannot provide a more detailed analysis. You can find more information on the FDA's website or by searching the pharmaceutical company's website.

Sources:

[1] DrugPatentWatch.com - a website providing up-to-date information on pharmaceutical patents and patent expirations.

Please note: Due to the specificity of your question, I have tried to provide a general overview of the process rather than a detailed analysis of a specific medication. For specific information on Winrevair, I recommend visiting the FDA's website or the website of the pharmaceutical company that produces it.



Other Questions About Winrevair :

Insurance prefer generics over winrevair? What is the fda status of a generic winrevair? Winrevair biosimilar equivalents or biosimilars? Winrevair patent number? Winrevair biosimilar equivalents or generic or biosimilar? Generic alternatives to winrevair pah? Winrevair endothelin receptor antagonists?

AI-Drug Label Prescribing Information Alignment Report

86
86%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The AI response is largely consistent with the provided label excerpts for indication and clinical-study efficacy endpoints, but it does not present the full exact label claims and also does not evaluate other label-required domains (dose/safety/contraindications), limiting verification against the prescribing information.


Category Scores

Indication
95
Excellent
Dosage
50
Good

Accurate Statements

WINREVAIR is indicated for adults with pulmonary arterial hypertension (PAH Group 1) to improve exercise capacity and WHO functional class and to reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation, and death.
Section 1 (INDICATIONS AND USAGE) provided in prompt.
Section 14.1 (Clinical Studies) provides supporting efficacy evidence for these endpoints in STELLAR and ZENITH, including improvement in WHO functional class/exercise capacity and reduced death/PAH clinical worsening events including lung transplantation and PAH hospitalization ≥24 hours.
Section 14.1 excerpts provided in prompt (STELLAR and ZENITH).
The provided evidence summary claims the label explicitly states the benefits and that Clinical Studies support those endpoints.
Consistent with the prompt’s supplied Section 1 and Section 14.1 excerpts.

Unsupported Statements

The response could not determine label adherence in general because the actual FDA-approved label text was not provided in the AI response.
The prompt did provide specific label excerpts (Section 1 and Section 14.1). The stated inability to verify is therefore not fully supported with respect to the indication/efficacy claims; however, it is partially reasonable for other unaddressed sections.

Contradictions


Important Omissions

No evaluation of dosing and administration, contraindications, boxed warnings, warnings/precautions, drug interactions, specific population statements, adverse reactions, monitoring, and storage/handling.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response concerns indication and efficacy endpoints only; it does not contain safety/dosing assertions that could directly conflict with labeling. The main limitation is incomplete label-domain coverage rather than an explicit incorrect safety claim.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Verification note is overly broad: the prompt already included label excerpts supporting indication/endpoint alignment, but the response claims insufficient information without clarifying that the unverified portions are outside indication/efficacy.

Suggested Improvement
Limit the ‘cannot_determine’/insufficient-information rationale to label sections not actually evaluated (e.g., dosing, contraindications, boxed warnings, safety/monitoring), and directly confirm the indication wording and endpoint definitions using the supplied excerpts.

Drug Brand Mention Assessment

Branding Score
12
Visibility
8
Mentioned
Ranking
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Winrevair is a brand name for a medication that is likely to be a generic version of a well-known asthma treatment.
Differentiators

Pricing Perception: Not Mentioned